From import dependence to global leadership, the next phase of growth must be driven not only by manufacturing scale and policy support, but also by innovation, research, and globally competitive healthcare technologies
The platform created by NIT Rourkela researchers is capable of delivering rapid, accurate, and repeatable imaging results with minimal human intervention
The device screens for conditions like diabetic retinopathy, glaucoma, age-related macular degeneration, cataract and refractive error, in under ten minutes per patient
The newly licensed platform enables precise control over both the drug-to-antibody ratio and payload attachment sites in single- and dual-payload ADCs
The new facility marks Align’s first manufacturing presence in India and its fourth globally
India already has talent, digital infrastructure, entrepreneurial energy, clinical expertise, and policy momentum. The next phase demands coordinated execution and building institutions that can hold the ecosystem together over time
We are contributing to the Indian pharmaceutical and laboratory sectors through advanced analytical instrumentation, automated liquid handling, and molecular biology solutions. Our technologies empower research and Quality Control (QC) by ensuring regulatory compliance and streamlined workflows…
Our Global Capability Center (GCC) in Bengaluru drives our major software development initiatives. Complementing this, our Bengaluru facility manufactures antibodies for research and diagnostics. Through these integrated technology and biotech operations, we are proud to contribute to India’s growth story in the life sciences sector.
Organizations that embrace it thoughtfully today will help shape a healthier tomorrow, for India and beyond
The product has received tentative USFDA approval, Health Canada notice of compliance, and Indian regulatory approval
Subscribe To Our Newsletter & Stay Updated
